ClinicalTrials.gg

Program

mRNA COVID-19 Vaccine

Also written as “COVID-19 mRNA vaccine”, “COVID-19 mRNA Vaccine (ZSVG-02-O)” and “COVID-19 mRNA Vaccine (nucleoside modified)”.

Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections · Influenza, Human · Severe Acute Respiratory Syndrome, led by 10 companies.

Furthest: phase 3, since May 12, 202213 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CanSino Biologics20 open or runningphase 2since May 12, 2022May 12, 2022none ahead
CNBG-Virogin Biotech (Shanghai)22 open or runningphase 2since Oct 31, 2023Oct 31, 2023none ahead
Sanofi20 open or runningphase 2since Mar 11, 2021Mar 11, 2021none ahead
Argorna Pharmaceuticals10 open or runningphase 1since May 28, 2023May 28, 2023none ahead
Bayer10 open or runningphase 3since Apr 16, 2021Apr 16, 2021none ahead
GlaxoSmithKline10 open or runningphase 3since Apr 16, 2024Apr 16, 2024none ahead
Invivyd10 open or runningphase 3since Jun 8, 2026Jun 8, 2026none ahead
Stemirna Therapeutics10 open or runningphase 2since Nov 11, 2021Nov 11, 2021none ahead
Vaccine10 open or runningphase 1since Jul 5, 2023Jul 5, 2023none ahead
Walvax Biotechnology10 open or runningphase 3since Apr 13, 2021Apr 13, 2021none ahead

Also a collaborator on its studies: Abogen Biosciences and BioNTech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2021First study: phase 2 study in COVID-19New to SanofiSanofi · NCT04798027 · 182 enrolled · United States, Australia, Brazil and more
  2. Apr 13, 2021Walvax Biotechnology’s first study: phase 3 study in COVID-19New to Walvax BiotechnologyWalvax Biotechnology · NCT04847102 · 28,000 enrolled · Indonesia, Mexico
  3. Apr 16, 2021Bayer’s first study: phase 3 study in COVID-19New to BayerBayer · NCT04848467
  4. Jul 16, 2021Phase 2 study in Influenza, HumanSanofi · NCT04969276 · 306 enrolled · United States
  5. Nov 11, 2021Stemirna Therapeutics’ first study: phase 2 study in COVID-19New to Stemirna TherapeuticsStemirna Therapeutics · NCT05144139 · 480 enrolled · Lao People's Democratic Republic
  6. May 12, 2022CanSino Biologics’ first study: phase 1 study in COVID-19New to CanSino BiologicsCanSino Biologics · NCT05373485 · 43 enrolled · China
  7. May 12, 2022Phase 2 study in COVID-19CanSino Biologics · NCT05373472 · 150 enrolled · China
  8. May 28, 2023Argorna Pharmaceuticals’ first study: phase 1 study in SARS-CoV-2New to Argorna PharmaceuticalsArgorna Pharmaceuticals · NCT05897190 · 60 enrolled · China
  9. Jul 5, 2023Vaccine’s first study: phase 1 study in Severe Acute Respiratory SyndromeNew to VaccineVaccine · NCT05938075 · 130 enrolled · South Africa
  10. Oct 31, 2023CNBG-Virogin Biotech (Shanghai)’s first study: phase 1 study in COVID-19New to CNBG-Virogin Biotech (Shanghai)CNBG-Virogin Biotech (Shanghai) · NCT06113744 · 164 planned · China
  11. Oct 31, 2023Phase 2 study in COVID-19CNBG-Virogin Biotech (Shanghai) · NCT06113731 · 980 planned · China
  12. Apr 16, 2024GlaxoSmithKline’s first study: phase 3 study in Respiratory Syncytial Virus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT06374394 · 841 enrolled · United States, Belgium, Netherlands and more
  13. Jun 8, 2026Invivyd’s first study: phase 3 study in COVID-19New to InvivydInvivyd · NCT07655180 · 210 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“mRNA COVID-19 Vaccine”name, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07655180COVID-19 · United States3CompletedInvivydAug 15, 2026210
NCT06374394Respiratory Syncytial Virus Infections · United States, Belgium, Netherlands and more3CompletedGlaxoSmithKlineNov 1, 2024841
NCT06113744COVID-19 · China1RecruitingCNBG-Virogin Biotech (Shanghai)Jun 30, 2023164
NCT06113731COVID-19 · China2RecruitingCNBG-Virogin Biotech (Shanghai)Oct 30, 2023980
NCT05938075Severe Acute Respiratory Syndrome · South Africa1CompletedVaccineJul 25, 2024130
NCT05897190SARS-CoV-2 · China1CompletedArgorna PharmaceuticalsJun 13, 202260
NCT05373485COVID-19 · China1CompletedCanSino BiologicsAug 8, 202243
NCT05373472COVID-19 · China2CompletedCanSino BiologicsSep 21, 2022150
NCT05144139COVID-19 · Lao People's Democratic Republic2CompletedStemirna TherapeuticsAug 28, 2022480
NCT04969276Influenza, Human · United States2CompletedSanofiFeb 8, 2022306
NCT04848467COVID-193WithdrawnBayerNov 30, 20210
NCT04847102COVID-19 · Indonesia, Mexico3UNKNOWNWalvax BiotechnologyNov 30, 202128,000
NCT04798027COVID-19 · United States, Australia, Brazil and more2TerminatedSanofiJun 27, 2022182

How it is read

Names in the registry

  • “COVID-19 mRNA vaccine”, 6 entries
  • “COVID-19 mRNA Vaccine (ZSVG-02-O)”, 2 entries
  • “COVID-19 mRNA Vaccine (nucleoside modified)”, 1 entry
  • “SARS-CoV-2 mRNA vaccine formulation 1”, 1 entry
  • “SARS-CoV-2 mRNA vaccine formulation 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.